Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Adds Infectious Disease Tests With Luxembourg's Fast-Track Diagnostics

Executive Summary

Siemens Healthineers has signed an agreement to acquire Luxembourg-based Fast Track Diagnostics (FTD) the developer of diagnostics that can distinguish between viral, bacterial, or other infections in one test. The deal comes as Siemens is shaping up to float Healthineers, as an independently publicly-listed company.

You may also be interested in...

M&A Analysis: October Notches 30 Deals In Big M&A Boom

The medtech M&A deal count soared in October with a total of 30 deals announced and closed in the month. It was an especially busy month for the orthopedics sector, with a number of high profile deals inked.

Confirmed: Siemens Aims For H1 2018 IPO for Healthineers

Siemens is planning to spin out its Healthineers business in an IPO slated for the first half of next year, the German conglomerate has confirmed. The move will give the health care business "the required currency and entrepreneurial flexibility" to grow in a fundamentally attractive market, it said. The announcement was made in conjunction with the group's reporting of its third quarter results for fiscal 2017, in which solid diagnostics imaging sales helped to boost the top line for Healthineers.

Biocartis, Fast-track eye 2017 launch of respiratory infection panel for Idylla

Biocartis is partnering with Fast-track diagnostics to develop syndromic multiplex tests that will run on Biocartis’ Idylla analyzer and the first assay is expected to be ready two years from now.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts